Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN D CARTER

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1447269238
CMS profile
246725
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$48,544.25

63 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $27,914.49 27
ABBVIE INC. $20,629.76 36

Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN D CARTER

NPI 1447269238 · CMS profile ID 246725

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447269238?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN D CARTER, NPI 1447269238, CMS profile ID 246725. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447269238?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOHN D CARTER, NPI 1447269238, CMS profile ID 246725. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447269238?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOHN D CARTER, NPI 1447269238, CMS profile ID 246725, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1447269238?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

63 matching records · $48,544.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 63 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–63 of 63.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $64.6503/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890714097 CMS
ABBVIE INC. $192.5803/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890714099 CMS
ABBVIE INC. $11.6303/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890714101 CMS
ABBVIE INC. $11.8003/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890714103 CMS
ABBVIE INC. $68.6703/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890714105 CMS
ABBVIE INC. $4.5903/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890714107 CMS
ABBVIE INC. $134.6403/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890714081 CMS
ABBVIE INC. $134.3003/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890714083 CMS
ABBVIE INC. $2,500.0003/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890714079 CMS
ABBVIE INC. $102.0002/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890714077 CMS
Amgen Inc. $1,740.0001/14/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939820859 CMS
Amgen Inc. $1,160.0001/14/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939820863 CMS
ABBVIE INC. $30.0001/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890714075 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $61,800.66 67
PY2020 $15,460.81 13
PY2021 $12,414.64 17
PY2022 $48,544.25 63
PY2023 $32,521.71 29
PY2024 $17,533.35 46
PY2025 $25,118.06 212

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,117,153.18 200
PY2024 Principal investigator $48,897.40 10
PY2023 Principal investigator $13,716.25 8
PY2022 Principal investigator $80,072.60 18
PY2021 Principal investigator $268,038.93 41
PY2020 Principal investigator $97,940.12 64
PY2019 Principal investigator $121,409.17 64

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

200 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $339.25 12/31/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH) No dispute reported 06/30/2026 1202535119
Principal investigator 1 ARGENX US, INC. $2,500.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148243
Principal investigator 1 ARGENX US, INC. $2,500.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148246
Principal investigator 1 ARGENX US, INC. $3,350.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148249
Principal investigator 1 ARGENX US, INC. $2,000.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148297
Principal investigator 1 ARGENX US, INC. $2,000.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148301
Principal investigator 1 ARGENX US, INC. $1,500.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148330
Principal investigator 1 ARGENX US, INC. $3,000.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148333
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,731.39 12/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289770
Principal investigator 1 Janssen Research & Development, LLC $2,450.00 12/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175394114
Principal investigator 1 ABBVIE INC. $18,890.00 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202528338
Principal investigator 1 ABBVIE INC. $5,735.00 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202528340
Principal investigator 1 ABBVIE INC. $2,327.50 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202528396
Principal investigator 1 ABBVIE INC. $12,514.50 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202528398
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,822.88 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288863
Principal investigator 1 ABBVIE INC. $5,360.30 11/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren s Disease (SjD) No dispute reported 06/30/2026 1202525436
Principal investigator 1 ARGENX US, INC. $726.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148233
Principal investigator 1 ARGENX US, INC. $726.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148236
Principal investigator 1 ARGENX US, INC. $726.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148239
Principal investigator 1 ARGENX US, INC. $5,895.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148285
Principal investigator 1 ARGENX US, INC. $5,895.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148290
Principal investigator 1 ARGENX US, INC. $5,895.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148294
Principal investigator 1 ARGENX US, INC. $1,881.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148344
Principal investigator 1 ARGENX US, INC. $1,881.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148347
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $26,457.32 11/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288489
Principal investigator 1 ABBVIE INC. $1,212.30 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202523803
Principal investigator 1 ABBVIE INC. $6,120.00 11/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202523621
Principal investigator 1 ABBVIE INC. $52,830.00 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202521341
Principal investigator 1 ABBVIE INC. $63,625.50 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202521343
Principal investigator 1 Amgen Inc. $50,428.03 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246640339
Principal investigator 1 GlaxoSmithKline, LLC. $37,123.02 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192163538
Principal investigator 1 ABBVIE INC. $3,271.25 11/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520089
Principal investigator 1 Janssen Research & Development, LLC $5,200.00 11/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175394227
Principal investigator 1 ABBVIE INC. $1,398.60 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202518379
Principal investigator 1 ABBVIE INC. $1,200.00 10/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202518139
Principal investigator 1 ABBVIE INC. $1,216.00 10/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202518141
Principal investigator 1 ARGENX US, INC. $3,470.00 10/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148266
Principal investigator 1 ARGENX US, INC. $3,470.00 10/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148270
Principal investigator 1 ARGENX US, INC. $3,470.00 10/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148274
Principal investigator 1 ARGENX US, INC. $726.00 10/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148277
Principal investigator 1 ARGENX US, INC. $726.00 10/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148281
Principal investigator 1 ARGENX US, INC. $1,881.00 10/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148317
Principal investigator 1 ARGENX US, INC. $1,881.00 10/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148321
Principal investigator 1 ARGENX US, INC. $5,936.00 10/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148326
Principal investigator 1 ABBVIE INC. $7,834.05 10/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202516987
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,816.44 10/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286947
Principal investigator 1 ABBVIE INC. $5,735.00 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202515815
Principal investigator 1 ABBVIE INC. $7,575.00 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren s Disease (SjD) No dispute reported 06/30/2026 1202515841
Principal investigator 1 Janssen Research & Development, LLC $6,700.00 10/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175394246
Principal investigator 1 ARGENX US, INC. $726.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148197
Principal investigator 1 ARGENX US, INC. $1,881.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148201
Principal investigator 1 ARGENX US, INC. $5,835.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148205
Principal investigator 1 ARGENX US, INC. $726.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148211
Principal investigator 1 ARGENX US, INC. $726.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148213
Principal investigator 1 ARGENX US, INC. $726.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148217
Principal investigator 1 ARGENX US, INC. $726.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148221
Principal investigator 1 ARGENX US, INC. $726.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148225
Principal investigator 1 ARGENX US, INC. $1,881.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148229
Principal investigator 1 ARGENX US, INC. $1,921.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148255
Principal investigator 1 ARGENX US, INC. $1,921.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148259
Principal investigator 1 ARGENX US, INC. $1,921.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148263
Principal investigator 1 ARGENX US, INC. $4,560.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148305
Principal investigator 1 ARGENX US, INC. $4,560.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148310
Principal investigator 1 ARGENX US, INC. $5,895.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148313
Principal investigator 1 ARGENX US, INC. $6,402.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148336
Principal investigator 1 ARGENX US, INC. $6,402.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148341
Principal investigator 1 ARGENX US, INC. $1,928.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148351
Principal investigator 1 ARGENX US, INC. $1,806.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148355
Principal investigator 1 ARGENX US, INC. $1,806.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148358
Principal investigator 1 ARGENX US, INC. $1,806.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148363
Principal investigator 1 ARGENX US, INC. $726.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148367
Principal investigator 1 ARGENX US, INC. $726.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148371
Principal investigator 1 ARGENX US, INC. $726.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148375
Principal investigator 1 GlaxoSmithKline, LLC. $30,633.57 10/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192163533
Principal investigator 1 ABBVIE INC. $157.98 09/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202512832
Principal investigator 1 ABBVIE INC. $7,500.00 09/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202512834
Principal investigator 1 SANOFI US SERVICES INC. $2,750.00 09/29/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226143930
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,995.68 09/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285720
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192163530
Principal investigator 1 ABBVIE INC. $13,500.00 09/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren s Disease (SjD) No dispute reported 06/30/2026 1202509248
Principal investigator 1 ABBVIE INC. $2,462.50 09/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202507709
Principal investigator 1 ARGENX US, INC. $37.60 09/03/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148800
Principal investigator 1 ARGENX US, INC. $179.00 09/03/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148805
Principal investigator 1 ARGENX US, INC. $51.75 09/03/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148808
Principal investigator 1 ARGENX US, INC. $4.90 09/03/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148813
Principal investigator 1 ARGENX US, INC. $477.50 09/03/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148820
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,958.23 09/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284921
Principal investigator 1 SANOFI US SERVICES INC. $1,928.15 08/25/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226143922
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,855.25 08/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284519
Principal investigator 1 ABBVIE INC. $2,280.00 08/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202505377
Principal investigator 1 ABBVIE INC. $10,000.00 08/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202504691
Principal investigator 1 ABBVIE INC. $7,500.00 08/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202504369
Principal investigator 1 ARGENX US, INC. $6,402.00 08/13/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148755
Principal investigator 1 ARGENX US, INC. $3,470.00 08/13/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148758
Principal investigator 1 ARGENX US, INC. $1,881.00 08/13/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148762
Principal investigator 1 ARGENX US, INC. $4,560.00 08/13/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148769
Principal investigator 1 ARGENX US, INC. $4,560.00 08/13/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148773
Principal investigator 1 SANOFI US SERVICES INC. $11,850.00 08/11/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226143919
Principal investigator 1 ARGENX US, INC. $162.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148717
Principal investigator 1 ARGENX US, INC. $264.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148733
Principal investigator 1 ARGENX US, INC. $216.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148736
Principal investigator 1 ARGENX US, INC. $54.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148739
Principal investigator 1 ARGENX US, INC. $1,113.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148743
Principal investigator 1 ARGENX US, INC. $303.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148747
Principal investigator 1 ARGENX US, INC. $55.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148751
Principal investigator 1 ARGENX US, INC. $507.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148766
Principal investigator 1 ARGENX US, INC. $285.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148777
Principal investigator 1 ARGENX US, INC. $101.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148781
Principal investigator 1 ARGENX US, INC. $2.45 08/04/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148816
Principal investigator 1 SANOFI US SERVICES INC. $3,815.60 08/04/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226143912
Principal investigator 1 SANOFI US SERVICES INC. $1,380.00 08/04/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226143915
Principal investigator 1 ARGENX US, INC. $1,881.00 07/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148722
Principal investigator 1 ARGENX US, INC. $5,895.00 07/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148725
Principal investigator 1 ARGENX US, INC. $1,806.00 07/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148729
Principal investigator 1 ARGENX US, INC. $726.00 07/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148784
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,040.19 07/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282960
Principal investigator 1 ARGENX US, INC. $132.50 07/01/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148789
Principal investigator 1 ARGENX US, INC. $18.80 07/01/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148793
Principal investigator 1 ARGENX US, INC. $143.25 07/01/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148797
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 07/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282018
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,855.25 06/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223281872
Principal investigator 1 ARGENX US, INC. $3,052.95 06/23/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148147
Principal investigator 1 ARGENX US, INC. $726.00 06/23/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148150
Principal investigator 1 ARGENX US, INC. $3,470.00 06/23/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148153
Principal investigator 1 ARGENX US, INC. $413.95 06/23/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148158
Principal investigator 1 ARGENX US, INC. $726.00 06/23/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148162
Principal investigator 1 ARGENX US, INC. $1,707.50 06/23/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148180
Principal investigator 1 ARGENX US, INC. $5,895.00 06/23/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148183
Principal investigator 1 ARGENX US, INC. $4,560.00 06/23/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148186
Principal investigator 1 ARGENX US, INC. $6,402.00 06/23/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148189
Principal investigator 1 ARGENX US, INC. $214.80 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148379
Principal investigator 1 ARGENX US, INC. $668.50 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148385
Principal investigator 1 ARGENX US, INC. $39.75 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148390
Principal investigator 1 ARGENX US, INC. $119.25 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148394
Principal investigator 1 ARGENX US, INC. $132.50 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148399
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148403
Principal investigator 1 ARGENX US, INC. $18.80 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148407
Principal investigator 1 ARGENX US, INC. $37.60 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148412
Principal investigator 1 ARGENX US, INC. $35.80 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148415
Principal investigator 1 ARGENX US, INC. $35.80 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148419
Principal investigator 1 ARGENX US, INC. $644.40 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148423
Principal investigator 1 ARGENX US, INC. $107.40 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148427
Principal investigator 1 ARGENX US, INC. $955.00 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148431
Principal investigator 1 ARGENX US, INC. $429.75 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148434
Principal investigator 1 ARGENX US, INC. $955.00 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148437
Principal investigator 1 ARGENX US, INC. $7.70 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148440
Principal investigator 1 ARGENX US, INC. $5.25 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148443
Principal investigator 1 ARGENX US, INC. $5.60 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148447
Principal investigator 1 ARGENX US, INC. $14.00 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148450
Principal investigator 1 ARGENX US, INC. $1.40 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148454
Principal investigator 1 ARGENX US, INC. $258.00 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148457
Principal investigator 1 ARGENX US, INC. $517.50 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148461
Principal investigator 1 ARGENX US, INC. $85.40 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148464
Principal investigator 1 ARGENX US, INC. $501.20 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148469
Principal investigator 1 ARGENX US, INC. $56.40 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148472
Principal investigator 1 ARGENX US, INC. $119.25 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148474
Principal investigator 1 ARGENX US, INC. $12.95 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148477
Principal investigator 1 ARGENX US, INC. $47.75 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148480
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148483
Principal investigator 1 ARGENX US, INC. $191.00 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148487
Principal investigator 1 ARGENX US, INC. $0.70 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148490
Principal investigator 1 ARGENX US, INC. $573.00 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148493
Principal investigator 1 ARGENX US, INC. $159.00 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148497
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,124.98 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223281580
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 06/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280690
Principal investigator 1 ABBVIE INC. $13,500.00 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202488937
Principal investigator 1 ABBVIE INC. $2,462.50 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202488939
Principal investigator 1 ABBVIE INC. $13,500.00 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202488941
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 06/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175394275
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 06/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280558
Principal investigator 1 ARGENX US, INC. $5,494.05 05/19/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148132
Principal investigator 1 ARGENX US, INC. $3,556.00 05/19/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148136
Principal investigator 1 ARGENX US, INC. $3,470.00 05/19/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148139
Principal investigator 1 ARGENX US, INC. $1,921.00 05/19/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148143
Principal investigator 1 ARGENX US, INC. $1,806.00 05/19/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148171
Principal investigator 1 SANOFI US SERVICES INC. $7,250.00 05/19/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226143894
Principal investigator 1 ABBVIE INC. $6,000.00 05/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202484993
Principal investigator 1 Janssen Research & Development, LLC $3,700.00 05/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175394148
Principal investigator 1 SANOFI US SERVICES INC. $16,200.00 05/12/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226143882
Principal investigator 1 SANOFI US SERVICES INC. $23,750.00 05/12/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226143886
Principal investigator 1 ABBVIE INC. $2,327.50 05/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481379
Principal investigator 1 ARGENX US, INC. $1,200.00 05/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148167
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,070.00 05/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223278764
Principal investigator 1 ARGENX US, INC. $4,560.00 04/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148122
Principal investigator 1 ARGENX US, INC. $1,806.00 04/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148126
Principal investigator 1 ARGENX US, INC. $1,921.00 04/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148129
Principal investigator 1 ARGENX US, INC. $726.00 04/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148175
Principal investigator 1 ARGENX US, INC. $1,336.30 04/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148193
Principal investigator 1 Janssen Research & Development, LLC $13,550.00 04/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175394185
Principal investigator 1 Janssen Research & Development, LLC $14,500.00 04/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175394211
Principal investigator 1 Eli Lilly and Company $47,205.00 04/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187877907
Principal investigator 1 ABBVIE INC. $4,890.00 04/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202471745
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 04/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223277514
Principal investigator 1 Eli Lilly and Company $6,181.61 03/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187876789
Principal investigator 1 Amgen Inc. $53,548.23 03/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC - TAMPA
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgrens Syndrome No dispute reported 06/30/2026 1246640331
Principal investigator 1 ABBVIE INC. $4,050.00 03/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202461914
Principal investigator 1 Eli Lilly and Company $7,774.44 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187876793
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,135.69 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190301531
Principal investigator 1 Eli Lilly and Company $147,378.00 01/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187877553
Principal investigator 1 Amgen Inc. $5,000.00 01/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA-TAMPA
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246640351